Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01208961 · ClinicalTrials.gov registry record · Phase 2
Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation
A Phase 2 study of Severe Hypertriglyceridemia, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT01208961: Completed Phase 2 study of Severe Hypertriglyceridemia, sponsored by AstraZeneca.
NCT01208961 is a Phase 2 study of Severe Hypertriglyceridemia that has completed, run by AstraZeneca. The registered enrollment target is 54 participants, below the 418-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01208961, a Phase 2 study of Severe Hypertriglyceridemia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of this study are to compare the relative bioavailabilities of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma from a single dose of Epanova or Lovaza during periods of high- and low -fat consumption.
Primary Outcome
Analyses of the outcome measures presented are for baseline-adjusted data for total (esterified and unesterfied) EPA and DHA since the presence of endogenous levels of these fatty acids would likely contribute to intra-subject variability and affect the analyses and interpretation.
Conditions Studied
Interventions
- DRUG Epanova (4 g) and Lovaza (4 g)
- DRUG Lovaza (4 g) and Epanova (4 g)
Study Locations (1)
Illinois
- Radiant Research - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2010-09 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
What the finished NCT01208961 record still lists
NCT01208961 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 418-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Severe Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which Epanova (4 g) and Lovaza (4 g) is the first listed.
NCT01208961 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT01208961 about?
NCT01208961 is a clinical study titled "Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation". The objectives of this study are to compare the relative bioavailabilities of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma from a single dose of Epanova or Lovaza during periods of high- and low -fat consumption.
What is the current status of trial NCT01208961?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2010-09. Estimated completion is 2010-11.
What conditions does trial NCT01208961 study?
This clinical trial studies the following conditions: Severe Hypertriglyceridemia.
What interventions are being tested in trial NCT01208961?
The interventions under investigation include: Epanova (4 g) and Lovaza (4 g) (DRUG), Lovaza (4 g) and Epanova (4 g) (DRUG).
Who is sponsoring clinical trial NCT01208961?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01208961 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Hypertriglyceridemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01208961's enrollment target sits among peer trials
54 9th of 8 the lowest of 8 other Severe Hypertriglyceridemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Severe Hypertriglyceridemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
RECRUITING · Phase 2
-
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
RECRUITING · Phase 3
-
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
ACTIVE NOT RECRUITING · Phase 3
-
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
-
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
-
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia